Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company developing RNA interference (RNAi) therapies for neurological diseases. Their divalent small interfering RNA (di-siRNA) platform enables durable gene silencing in the brain and spinal cord. The company is advancing a pipeline of disease-modifying treatments for Huntington’s disease, genetic epilepsy, and other neurological disorders.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $97M
Date: 28-Jan-2025
Investors: EQT Life Sciences, Sanofi Ventures, RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, GHR Foundation, F-Prime Capital
Markets: Biotechnology, RNAi, Neurological Diseases, Health Care, Life Science
HQ: Boston, Massachusetts, United States
Founded: 2018
Website: https://www.atalantatx.com/
LinkedIn: https://www.linkedin.com/company/atalanta-therapeutics
Twitter: https://twitter.com/AtalantaTx
Crunchbase: https://www.crunchbase.com/organization/atalanta-therapeutics
Leave a Comment
Comments
No comments yet.